Search | CADTH

Showing 1 - 10 results of 11

Adult B-Cell Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative () (Last Updated: Feb 24, 2021)

Provisional Funding Algorithm Stakeholder Input Deadline Dec 7, 2020 Draft Report Posted Jan 28, 2021 Stakeholder Feedback Deadline Feb 4, 2021 Final Report Posted Feb 24, 2021

Project Line:

Reimbursement Review

Project Status:

Complete

Colorectal Cancer () (Last Updated: Nov 12, 2021)

Provisional Funding Algorithm Stakeholder Input Deadline August 26, 2021 Draft Report Posted October 14, 2021 Stakeholder Feedback Deadline October 21, 2021 Final Report Posted November 12, 2021

Project Line:

Reimbursement Review

Project Status:

Complete

Metastatic Urothelial Carcinoma (mUC) () (Last Updated: Mar 28, 2022)

Provisional Funding Algorithm Draft Report Posted February 17, 2022 Stakeholder Feedback Deadline February 25, 2022 Final Report Posted March 28, 2022

Project Line:

Reimbursement Review

Project Status:

Complete

Adult Classical Hodgkin Lymphoma () (Last Updated: Feb 2, 2022)

Provisional Funding Algorithm Draft Report Posted December 16, 2021 Stakeholder Feedback Deadline January 04, 2022 Final Report Posted February 02, 2022

Project Line:

Reimbursement Review

HER2-Positive Metastatic Breast Cancer () (Last Updated: Apr 12, 2022)

Provisional Funding Algorithm Stakeholder Input Deadline January 07, 2022 Draft Report Posted February 10, 2022 Stakeholder Feedback Deadline February 17, 2022 Final Report Posted April 12, 2022...

Project Line:

Reimbursement Review

Project Status:

Complete

Unresectable Hepatocellular Carcinoma () (Last Updated: Apr 21, 2021)

Provisional Funding Algorithm Stakeholder Input Deadline Feb 1, 2021 Draft Report Posted Mar 18, 2021 Stakeholder Feedback Deadline Mar 25, 2021 Final Report Posted Apr 21, 2021

Project Line:

Reimbursement Review

Project Status:

Complete

Chronic Lymphocytic Leukemia () (Last Updated: Mar 25, 2021)

Provisional Funding Algorithm Stakeholder Input Deadline Feb 9, 2021 Draft Report Posted Mar 25, 2021 Stakeholder Feedback Deadline Apr 1, 2021 Final Report Posted (Target) May 13, 2021 Reason for...

Project Line:

Reimbursement Review

Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastric, Gastroesophageal Junction (GEJ), or Esophageal Cancer () (Last Updated: Jun 21, 2022)

Provisional Funding Algorithm Stakeholder Input Deadline: April 7, 2022 Draft Report Posted: May 12, 2022 Stakeholder Feedback Deadline: May 19, 2022 Final Report Posted : June 21, 2022

Project Line:

Reimbursement Review

Project Status:

Complete

Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer () (Last Updated: May 24, 2022)

Provisional Funding Algorithm Draft Report Posted March 24, 2022 Stakeholder Feedback Deadline April 07, 2022 Final Report Posted May 24, 2022

Project Line:

Reimbursement Review

Project Status:

Complete

Multiple myeloma () (Last Updated: May 25, 2022)

Provisional Funding Algorithm Stakeholder Input Deadline: March 10, 2022 Draft Report Posted: April 21, 2022 Stakeholder Feedback Deadline: April 28, 2022 Final Report Posted: May 25, 2022

Project Line:

Reimbursement Review

Project Status:

Complete

Current Filters

Adult B-Cell Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative () (Last Updated: Feb 24, 2021)

Colorectal Cancer () (Last Updated: Nov 12, 2021)

Metastatic Urothelial Carcinoma (mUC) () (Last Updated: Mar 28, 2022)

Adult Classical Hodgkin Lymphoma () (Last Updated: Feb 2, 2022)

HER2-Positive Metastatic Breast Cancer () (Last Updated: Apr 12, 2022)

Unresectable Hepatocellular Carcinoma () (Last Updated: Apr 21, 2021)

Chronic Lymphocytic Leukemia () (Last Updated: Mar 25, 2021)

Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastric, Gastroesophageal Junction (GEJ), or Esophageal Cancer () (Last Updated: Jun 21, 2022)

Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer () (Last Updated: May 24, 2022)

Multiple myeloma () (Last Updated: May 25, 2022)